Eularis Releases Update of Its Comprehensive Report on Maximizing the Bottom Line in Pharmaceutical Marketing
*(LOGO 72dpi: Send2Press.com/mediaboom/07-0924-Eularis_72dpi.jpg)
"The pharmaceutical environment is turbulent, and what used to work tocreate an industry-wide growth of 20 percent, no longer does," said the authorof the report, Dr. Andree K. Bates, president of Eularis. "As market growthslows, the bottom line return for brands is under increased scrutiny, andevery marketing dollar must count."
Eularis identified a common problem faced by pharmaceutical companies --how to know which activities impact market share and by how much. The companyassembled a group of world-leading mathematicians in the predictive analyticsfield, as well as thought leaders, to find the solution.
This report, in turn, analyzes how top pharmaceutical marketing leadersare handling pressing marketing return issues, and offers new ideas to apply.The detailed research addresses issues such as: ROI basics; practical skillsmarketers need for measuring marketing effectiveness; tools and best practicesthat make a difference; measurement principles that drive successful marketingmeasurement; how to propel strategy, growth, and bottom line return; plus anarray of case studies.
The report also explains what real people did to measure, improve, andprove bottom line return. It uncovers practices to predict how and wherepharmaceutical marketing and sales investments will yield the highest marketshare and market share price. Readers will benefit from the step-by-stepguidelines on successfully implementing approaches for real and measurableresults available only in this report.
Dr. Andree Bates, president of Eularis, has gained wide recognition withinthe international pharmaceutical industry for her expertise in marketingreturn analysis and is the author of this must-have report for allpharmaceutical industry marketers.
To purchase this report, visit: http://www.pharmamarketingroi.com.
Eularis provides sophisticated pharmaceutical analytics that providedata-driven insight into the financial impact of corporate and marketingdecisions. Unlike traditional analytics approaches which are lengthy andwhose reliance on historical or analogue data reduces their accuracy, Eularis'proprietary 94.8 Analytics Process is based on the current market situation.This proven approach helps pharmaceutical marketing teams to quickly plan,measure, validate, and optimize their sales and marketing performance.Eularis offers pre-launch analytics, marketing mix modeling (both professionaland consumer), portfolio optimization, sales force effectiveness, managed careanalytics, and patient compliance solutions. Co-headquartered in London andNew York City, the company has developed significant experience in the globalpharmaceutical market through client engagements with AstraZeneca,GlaxoSmithKline, Merck, Pfizer and many others.
For more information about Eularis, visit http://www.eularis.com.
This release was issued on behalf of the above organization bySend2Press(R), a unit of Neotrope(R). http://www.Send2Press.com
You May Also Like